China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there almost a year after Eisai and Biogen's anti-amyloid rival Leqembi (lecanemab), which was cleared by the NMPA in January.

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion),

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in China, Merck's deal with Hansoh for a new obesity drug, impending HIV medication availability,

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend approval for Biogen's drug, Leqembi, in paragraph 8) (Reuters) - China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's,